Ok Biotech Co Ltd - Asset Resilience Ratio
Ok Biotech Co Ltd (4155) has an Asset Resilience Ratio of 0.33% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how Ok Biotech Co Ltd's Asset Resilience Ratio has changed over time. Check asset allocation strategy of Ok Biotech Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Ok Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Ok Biotech Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$12.59 Million | 0.33% |
| Total Liquid Assets | NT$12.59 Million | 0.33% |
Asset Resilience Insights
- Limited Liquidity: Ok Biotech Co Ltd maintains only 0.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ok Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ok Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Bactiguard Holding AB (publ)
ST:BACTI-B |
Medical Devices | 8.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for Ok Biotech Co Ltd (2021–2025)
The table below shows the annual Asset Resilience Ratio data for Ok Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.33% | NT$12.59 Million ≈ $396.53K |
NT$3.85 Billion ≈ $121.28 Million |
-0.03pp |
| 2024-12-31 | 0.35% | NT$13.04 Million ≈ $410.89K |
NT$3.70 Billion ≈ $116.42 Million |
-1.03pp |
| 2023-12-31 | 1.38% | NT$42.31 Million ≈ $1.33 Million |
NT$3.07 Billion ≈ $96.64 Million |
+0.07pp |
| 2022-12-31 | 1.31% | NT$40.23 Million ≈ $1.27 Million |
NT$3.06 Billion ≈ $96.44 Million |
-0.28pp |
| 2021-12-31 | 1.59% | NT$44.78 Million ≈ $1.41 Million |
NT$2.81 Billion ≈ $88.62 Million |
-- |
About Ok Biotech Co Ltd
OK Biotech Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of blood glucose monitoring systems and homecare healthcare devices in Taiwan, the rest of Asia, America, Africa, and Europe. The company offers nebulizers, blood glucose meters, glucometers, blood sugar meters, and blood glucose test strips. It also provides OTC hearing aids, multi-f… Read more